Feret Wiktoria, Nalewajska Magdalena, Wojczyński Łukasz, Witkiewicz Wojciech, Kłos Patrycja, Dziedziejko Violetta, Pawlik Andrzej
Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Department of Cardiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
J Clin Med. 2021 Nov 15;10(22):5305. doi: 10.3390/jcm10225305.
The outburst of inflammatory response and hypercoagulability are among the factors contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a xanthine-derived drug registered for the treatment of vascular claudication, has been reported to display broad-spectrum anti-inflammatory and immunomodulatory properties via adenosine A2A receptor (A2AR)-related mechanisms, in parallel to its rheological actions. Prior studies have indicated the efficacy of PTX in the treatment of various pulmonary diseases, including the management of acute respiratory distress syndrome of infectious causes. Therefore, PTX has been proposed to have potential benefits in the treatment of SARS-CoV-2 symptoms, as well as its complications. The aim of this review is to discuss available knowledge regarding the role of PTX as a complementary therapeutic in SARS-CoV-2.
炎症反应爆发和高凝状态是导致重症 COVID-19 病例死亡率增加的因素之一。己酮可可碱（PTX）是一种已注册用于治疗血管性间歇性跛行的黄嘌呤衍生药物，据报道，它通过腺苷 A2A 受体（A2AR）相关机制发挥广谱抗炎和免疫调节特性，同时还具有流变学作用。先前的研究表明 PTX 在治疗各种肺部疾病方面有效，包括治疗感染性原因引起的急性呼吸窘迫综合征。因此，有人提出 PTX 在治疗 SARS-CoV-2 症状及其并发症方面可能具有潜在益处。本综述的目的是讨论关于 PTX 作为 SARS-CoV-2 辅助治疗作用的现有知识。
